Solu Therapeutics, a company developing a new type of antibody drug, unveiled

索鲁治疗公司（Solu Therapeutics），一家正在开发新型抗体药物的公司，公布了

$41 million in financing

4100万美元的融资

on Wednesday for clinical testing of a therapy with the potential to bring a safer and more effective approach to blood cancers.

周三，一种有可能为血液癌症带来更安全和更有效治疗方法的疗法进入了临床测试。

Boston-based Solu has already begun dosing patients in a Phase 1 test of lead program STX-0712 in resistant or refractory chronic myelomonocytic leukemia (CMML) and other hematologic malignancies. The target of the drug is CCR2, a receptor that plays a role in cancer development and progression. The Solu drug is intended to eliminate CCR2-positive cells.

总部位于波士顿的Solu公司已经开始在一项一期试验中对主要项目STX-0712进行给药，针对耐药或难治性慢性粒单核细胞白血病（CMML）及其他血液恶性肿瘤。该药物的靶点是CCR2，这是一种在癌症发展和进展中起作用的受体。Solu公司的药物旨在消除CCR2阳性的细胞。

It does so in a novel way..

它以一种新颖的方式做到了这一点。

Antibodies and small molecules are both well-established therapeutic modalities for treating cancer. Solu says its approach brings both modalities together to target cell surface proteins that cannot otherwise be addressed. The company uses small molecules to bind to elusive targets such as G protein-coupled receptors (GPCRs) and ion channels.

抗体和小分子都是治疗癌症的成熟方法。Solu表示其方法结合了这两种方式，以针对那些无法通过其他方式解决的细胞表面蛋白。该公司使用小分子来绑定难以捉摸的目标，例如G蛋白偶联受体（GPCR）和离子通道。

CCR2 is a GPCR..

CCR2 是一种 GPCR。

presented by

呈现者

Sponsored Post

赞助帖子

What Are the Best Medical Coding Outsourcing Companies?

最佳的医疗编码外包公司有哪些？

Outsourcing your medical coding can help ensure a healthy revenue cycle. Discover the best medical coding outsourcing companies and find the right one for you.

外包您的医疗编码可以帮助确保健康的收入周期。发现最好的医疗编码外包公司，并找到适合您的那一家。

By Global Healthcare Resources

由全球医疗保健资源提供

Solu’s molecules are bifunctional, with one arm that binds to the cell surface target and another arm that links to a proprietary antibody. Doing so imbues the therapy with the properties and functions of an antibody, such as longer durability in the body. Solu says this approach could offer a more targeted and effective treatment with minimal effects on healthy tissue..

Solu的分子是双功能的，一只手臂与细胞表面目标结合，另一只手臂则连接到一种专利抗体。这样做使该疗法具备了抗体的特性和功能，例如在体内更长的持久性。Solu表示，这种方法可以提供更有针对性且更有效的治疗，同时对健康组织的影响最小。

“By directly depleting the CCR2-positive malignant monocytes driving CMML, STX-0712 has the potential to offer a highly specific and targeted therapy for patients who currently have limited treatment options available,” Chief Medical Officer Sergio Santillana said in a prepared statement.

“通过直接消耗驱动CMML的CCR2阳性恶性单核细胞，STX-0712有可能为目前治疗选择有限的患者提供一种高度特异性和针对性的疗法，”首席医学官塞尔吉奥·桑蒂利亚纳在一份准备好的声明中说道。

During the annual meeting of the American Society of Hematology last December,

在去年12月的美国血液学会年会期间，

Solu presented data

索鲁展示了数据

showing STX-0712 successfully depleted CCR2-positive cells in patient samples of CMML and acute myeloid leukemia. Tests of the drug in monkeys showed it was safe and well tolerated with a favorable pharmacokinetic profile.

显示STX-0712成功消耗了CMML和急性髓性白血病患者样本中的CCR2阳性细胞。该药物在猴子体内的测试表明其安全且耐受性良好，具有良好的药代动力学特性。

Solu’s platform technology, called Cytotoxicity Targeting Chimera (CyTac), and its drug candidates, were licensed from GSK. The startup was founded by venture capital firm Longwood Fund.

Solu的平台技术称为细胞毒性靶向嵌合体（CyTac），其候选药物是从GSK获得许可的。这家初创公司由风险投资公司Longwood Fund创立。

Solu emerged in 2023

索鲁于2023年出现。

backed by $31 million in seed financing from Longwood and Santé Ventures. Beyond cancer, the company says its approach could have applications to immunology and other therapeutic areas.

公司在来自Longwood和Santé Ventures的3100万美元种子轮融资支持下，表示其方法除了应用于癌症外，还可能在免疫学和其他治疗领域有应用。

presented by

由...呈现

Health Tech

健康科技

The 5 Best Software to Buy for Managing a Spa Franchise

管理水疗连锁店必买的5款最佳软件

Choosing the right software translates directly into better client management, operational efficiency and growth for your spa franchise. Discover which tool is best for your business.

选择合适的软件可以直接转化为更好的客户管理、运营效率以及您的水疗加盟店的增长。发现哪种工具最适合您的业务。

By Meevo

由 Meevo 制作

The Series A financing announced Wednesday added new investors Eli Lilly & Company, Biovision Ventures, Pappas Capital, Hengdian Group Capital, and The Leukemia & Lymphoma Society Therapy Acceleration Program. Longwood and Santé also participated in the new financing along with other earlier investors DCVC Bio, Astellas Venture Management, and Alexandria Venture Investments..

周三宣布的 A 轮融资新增了礼来公司、Biovision Ventures、Pappas Capital、横店集团资本以及白血病和淋巴瘤学会治疗加速计划等投资者。Longwood 和 Santé 也与之前的投资者 DCVC Bio、安斯泰来风险投资管理公司和 Alexandria Venture Investments 一起参与了新一轮融资。

With the new capital, Solu plans to complete dose escalation and expansion of its lead CMML program. The company also plans to develop additional drug candidates, including what it describes as a novel, first-in-class mast cell depletor for immunological diseases. Furthermore, Solu plans to start new discovery programs targeting pathogenic cells and explore of new applications for its platform technologies..

有了新的资金，Solu 计划完成其主要 CMML 项目的剂量递增和扩展。该公司还计划开发额外的候选药物，包括一种据称是新型的、首创的肥大细胞清除剂用于免疫疾病。此外，Solu 计划启动针对致病细胞的新发现项目，并探索其平台技术的新应用。

Photo by Flickr user

照片由Flickr用户拍摄

Ed Uthman

埃德·乌特曼

via a Creative Commons

通过知识共享

license

许可证